BofA raised the firm’s price target on BeiGene to $198 from $181.50 and keeps a Neutral rating on the shares after analyzing the company’s drug sales performance in June. The firm says BeiGene’s on-track pipeline development is balanced by intense competition in the domestic market.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BGNE: